pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Midterm elections could reshape health policy, Medicare Advantage and insurance, STAT analysis says

Nov 3, 2026·read at STAT ↗Neutral

STAT's D.C. Diagnosis newsletter looks at how the upcoming midterm elections may influence health policy, Medicare Advantage programs and health insurance markets.

With record early voting turnout, the results could shift legislative focus and affect funding, regulation and access to health care services across the country.

The piece is available to STAT+ subscribers and includes the author's invitation for readers to share tips or concerns via Signal.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: What do the midterms mean for health care?”

read at STAT ↗
422 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
(aeruginascin + baeocystin + psilocybin)MYCO-003Oral PsilocybinPsilocybin (Microneedle Patch)psilocybin
topics
Cardiology2

related stories

  • Sep 14Psychedelic therapies ride wave of public favor into FDA hearingBioSpace
  • Aug 20Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a studySTAT
  • Jul 16Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsBioPharma Dive
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • May 6Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?STAT